Quarterly report pursuant to Section 13 or 15(d)

INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative)

v3.24.2.u1
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Oct. 12, 2018
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Intellectual Property [Member]          
Amortization expense   $ 295 $ 294 $ 589 $ 589
Accumulated amortization   $ 6,762   $ 6,762  
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]          
Patent acquired $ 15,200        
Estimated useful lives 13 years